Table 3.
Non-severe ALD (n=13) | Severe ALD (n=37) | Health control (n=25) | P value | |
---|---|---|---|---|
Age | 46.31 ± 8.85 | 53.78 ± 8.58 | 39.76 ± 8.66 | <0.001 |
Gender | male | male | male | / |
ALT (U/L) | 32.80 (17.55, 69.05) | 19.00 (13.00, 31.00) | 19.40 (13.10, 21.40) | 0.036 |
AST (U/L) | 26.80 (19.15, 55.95) | 28.60 (19.60, 47.80) | 16.50 (13.50, 18.80) | <0.001 |
ALB (g/L) | 46.10 (33.83, 47.83) | 33.00 (29.20, 40.20) | 48.30 (47.23, 49.43) | <0.001 |
Tbil (µmol/L) | 13.10 (9.85, 16.50) | 26.30 (15.60, 52.20) | 12.20 (8.75, 13.00) | <0.001 |
ALP (U/L) | 76.80 (65.40, 133.55) | 89.45 (70.98, 131.40) | 74.80 (65.15, 88.00) | 0.054 |
GGT (U/L) | 97.20 (34.05, 300.40) | 40.40 (27.80, 76.80) | 18.30 (14.02, 28.70) | <0.001 |
TC (mmol/L) | 3.8 ± 1.1 | 2.9 ± 0.9 | 4.0 ± 0.8 | 0.002 |
PLT (109/L) | 211 (132, 271) | 75 (56, 114) | 262 (218, 301) | <0.001 |
APRI | 0.17 (0.15, 0.38) | 0.40 (0.32, 0.70) | 0.06 (0.05, 0.08) | <0.001 |
FIB-4 | 1.23 (0.81, 2.25) | 5.31 (3.05, 6.81) | 0.52 (0.39, 0.68) | <0.001 |
AAR | 0.64 (0.58, 1.26) | 1.68 (1.03, 2.14) | 0.92 (0.78, 1.04) | <0.001 |
ALB, albumin; Tbil, total bilirubin; GGT, gamma-glutamyltransferase; TC, total cholesterol; PLT, platelet count; APRI, AST to platelet ratio index; FIB-4, fibrosis-4 index: age (years) × AST [U/L]/(platelets [109/L] × (ALT [U/L])1/2); AAR, aspartate aminotransferase-to-alanine aminotransferase ratio.
*P value of severe ALD group compared to non-severe ALD group. ALT P=0.041; AST P=0.745; ALB P=0.007; Tbil P=0.001; ALP P=0.301; GGT P=0.117; TC P=0.029; PLT P<0.001; APRI P=0.002; FIB4 P<0.001; AAR P=0.006.
P value of severe ALD group compared to HC group. ALT P=0.509; AST P<0.001; ALB P<0.001; Tbil P<0.001; ALP P=0.014; GGT P<0.001; TC P=0.001; PLT P<0.001; APRI P=0.002; FIB4 P<0.001; AAR P<0.001.
P value of non-severe ALD group compared to HC group. ALT P=0.010; AST P<0.001; ALB P=0.009; Tbil P=0.178; ALP P=0.517; GGT P<0.001; TC P=0.859; PLT P=0.075; APRI P=0.002; FIB4 P=0.001; AAR P=0.681.